Class I recalls
Recalling Manufacturer, Date Posted, Trade Name/Product, Reason for Recall
The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Recalling Manufacturer, Date Posted, Trade Name/Product, Reason for Recall
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Edwards Lifesciences (NYSE:EW) issued a recall of certain lots of Perimount replacement heart valves over concerns that they may have been contaminated with "extremely small" metallic particles during packaging.
New reports from the U.K.’s Medicines & Healthcare Products Regulatory Agency warn that even more women may have received breast implants with substandard silicone that’s prone to rupture.
The agency advised health care providers to begin assessing patients who received breast implants made by Poly Implant Prosthèse, expanding the warning which originally applied only to implants distributed after January 2001.
Covidien’s (NYSE:COV) confirmed today a global recall of its Roticulator single-use staplers, launched over packaging issues that may compromise the sterility of the devices.
The boxing match about the safety of St. Jude Medical’s newer Durata defibrillator lead reliability continues to spark interest in the EP community.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Patients with a common heart rhythm disorder who received treatment with cardiac ablation were arrhythmia-free longer than patients taking drugs, suggesting that ablation should be a 1st-order approach to managing an erratic heart beat, according to a new study.
Unveiled at this year’s Heart Rhythm Society in Boston, the study found that patients with paroxysmal atrial fibrillation who received ablation therapy were 20% less likely to see a recurrence than patients taking anti-arrhythmic medication.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
St. Jude Medical (NYSE:STJ) tried to distance its Durata defibrillator leads from their troubled Riata predecessor and unveiled the results of the decade-long SCD-HeFT heart failure study during separate presentations at this year’s Heart Rhythm Society meeting in Boston, Mass.
The quarrel between hip implant maker DePuy and researcher Deborah Cohen may be more than an academic altercation playing out in the pages of the esteemed British Medical Journal – it may be a preview of things to come.